medline.ch Onkologie Urologische Tumoren

	Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies. Cancer Evageliou NF, Renfro LA, Vallance KL, Varela CR, Benedetti DJ, Cost NG, Ehrlich PF, Kalapurakal JA, Khanna G, Aldrink JH, Glick RD, Ortiz MV, Parsons LN, Paulino AC, Artunduaga M, Smith EA, Dix DB, Fernandez CV, Dome JS, Geller JI, Mullen EA. PMID: 42751801 [PubMed - indexed for MEDLINE]
	Immunotherapy role in bladder cancer treatment: a review of literature. Front Oncol Thalambedu N, Vasipalli K, Sampath Kumar N, Vellanki S, Trikannad AK, Gullapalli M, Tu SM, Kunthur A. PMID: 42751111 [PubMed]
	Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer. Immunooncol Technol Scallo FM, Ishizuka JJ, Braun DA. PMID: 42751052 [PubMed]
	The use of artificial intelligence and wearable devices in enhanced recovery after surgery pathways following radical cystectomy: A systematic review. J Int Med Res Feyissa M, Baheer Y, Ahmed B, Rosa N, Dubey S, Thillaivasan K, Philippou Y, Odeh R, Muheilan M, Khetrapal P, Catto JW, Kelly JD, Chiruvella M, Vasdev N. PMID: 42750161 [PubMed - indexed for MEDLINE]
	Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease. Eur Radiol Kleiburg F, Heijmen L, Witteveen A, van Duuren K, Zuidgeest P, Smit F, de Geus-Oei LF, van der Hulle T. PMID: 42749930 [PubMed - as supplied by publisher]
	Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus Carlsson SV, van den Bergh R. PMID: 42749606 [PubMed - as supplied by publisher]
	Re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019. Eur Urol Longoni M, Gandaglia G, Montorsi F. PMID: 42749562 [PubMed - as supplied by publisher]
	Reply to Roberto Mario Scarpa's Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-12. Eur Urol Oncol Contieri R, Hurle R. PMID: 42749558 [PubMed - as supplied by publisher]
	Recognizing the significance of cancer-nerve crosstalk in advanced prostate cancer. Adv Cancer Res Bhattacharya S, Nag N, Singh SK, Datta K, Dutta S. PMID: 42749384 [PubMed - indexed for MEDLINE]
	[Molecular Diagnostics and Personalized Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)]. Aktuelle Urol Semmler M, Casuscelli J, Zschäbitz S, Jann JC. PMID: 42748971 [PubMed - as supplied by publisher]
	Natural product-derived compounds modulating STAT3 signaling in prostate cancer: Mechanistic insights and therapeutic potential. Biomed Pharmacother Feng Y, Liu D, Gu C, Zhou T, Zhang Z, Bonnet PA, Meng X. PMID: 42748829 [PubMed - as supplied by publisher]
	Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future. Clin Adv Hematol Oncol Saxena S, O'Hara J, Cao Q, Haik B, Choi JW, Koller C, Stifelman MD, Yerram N. PMID: 42748334 [PubMed - indexed for MEDLINE]
	Molecular profiling of apoptotic, inflammatory, and angiogenic markers in prostate cancer: Focus on p53, IL-6, IL-8, Bax/Bcl-2 ratio, and VEGF. Wiad Lek Al-Khafaji MH, Hameed WM, Shalla DM, Al-Salihi KA. PMID: 42748310 [PubMed - indexed for MEDLINE]
	Renal-clearable fluorescent probe for early detection of pancreatic cancer in living murine models. Sci Adv Huang M, Zhou Z, Zhang T, Xia X, Chen W, Wang E, Wang F, Ren J. PMID: 42748261 [PubMed - indexed for MEDLINE]
	Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming. Cancer Metastasis Rev Wang S, Xu X, Xu M, Wei Y, Qiao Y, Song X, Xie C, Zhou C, Yuan F. PMID: 42747576 [PubMed - indexed for MEDLINE]
	Integrated analysis of VEGFA rs833061 (-â€‰460Tâ€‰>â€‰C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype-phenotype association. Mol Biol Rep Kaushik R, Pawar D, Sharma A, Siwach K, Rohilla G, Narwal S, Khatri N, Arora A, Vashist M. PMID: 42747566 [PubMed - indexed for MEDLINE]
	Survival benchmarking of talazoparib plus enzalutamide in homologous recombination repair-deficient metastatic castration-resistant prostate cancer: a reconstructed individual patient data analysis. Jpn J Clin Oncol Tanaka H, Fukushima H, Tsukahara S, Shiota M, Yoshida S, Fujii Y. PMID: 42747074 [PubMed - as supplied by publisher]
	Assessing the Level of Prostate Cancer Care in a Low-Resource Setting: Disease Pattern, Current Situation of Care, and the Need for Reform-A Retrospective Observational Study From East Oncology Centre, Sudan. Adv Urol Alzubier MAA, Eltahir EA, Allah HMAA, Abubaker MM, Khalid SIO, Abdol AAIE, Daood MAA. PMID: 42746128 [PubMed]
	Lipid metabolic reprogramming in clear cell renal cell carcinoma: focus on high-density lipoprotein-related pathways. Oncol Rev Wu L, Xue H, Wu Y, Shen N, Yang Z, Gao L, Ma W, Wang C. PMID: 42745992 [PubMed]
	Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy. Cancer Lynch C, Arshad M, Rajeev-Kumar G, Che Y, Skolarus TA, Modi PK, Liauw SL. PMID: 42745507 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 181496

Seite 1 von 9075

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung